Biofunctionalization of Hydrogels for Engineering the Cellular Microenvironment

Micro-and Nanoengineering of the Cell Surface

Volumn , Issue , 2014, Pages 315-348

  Bhagawati, Maniraj ^a   Kumar, Sanjay ^a  

^a University of California at Berkeley   (United States)

Author keywords

Biodegradation; Extracellular matrix; Growth factor; Hydrogel; Matrix metalloproteinase; Nanoparticle; Protein immobilization

Indexed keywords

BIODEGRADATION; CELL ADHESION; CELLS; COMPLEX NETWORKS; CYTOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGELS; MOLECULAR BIOLOGY; NANOPARTICLES; PROTEINS; SUBSTRATES; SYNTHESIS (CHEMICAL); TISSUE ENGINEERING;

CELLULAR MICROENVIRONMENT; COVALENT IMMOBILIZATION; EXTRACELLULAR MATRICES; GROWTH FACTOR; HYDROGEL NANOPARTICLES; MATRIX METALLOPROTEINASES; PROTEIN IMMOBILIZATION; REGENERATIVE MEDICINE;

SCAFFOLDS (BIOLOGY);

EID: 84941749923     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-3146-6.00014-3     Document Type: Chapter

References (291)

1. Gjorevski N., Nelson C.M. Bidirectional extracellular matrix signaling during tissue morphogenesis. Cytokine Growth Factor Rev 2009, 20(5-6):459-465.
2. Tsang K.Y., Cheung M.C., Chan D., Cheah K.S. The developmental roles of the extracellular matrix: beyond structure to regulation. Cell Tissue Res 2010, 339(1):93-110.
3. Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009, 61(2):198-223.
4. Denys H., Braems G., Lambein K., Pauwels P., Hendrix A., De Boeck A., et al. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr Pharm Des 2009, 15(12):1373-1384.
5. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395-406.
6. Tanzer M.L. Current concepts of extracellular matrix. J Orthop Sci 2006, 11(3):326-331.
7. Bosman F.T., Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003, 200(4):423-428.
8. Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J Cell Sci 2010, 123(24):4195-4200.
9. Lu Q., Ganesan K., Simionescu D.T., Vyavahare N.R. Novel porous aortic elastin and collagen scaffolds for tissue engineering. Biomaterials 2004, 25(22):5227-5237.
10. Simionescu D.T., Lu Q., Song Y., Lee J.S., Rosenbalm T.N., Kelley C., et al. Biocompatibility and remodeling potential of pure arterial elastin and collagen scaffolds. Biomaterials 2006, 27(5):702-713.
11. Buijtenhuijs P., Buttafoco L., Poot A.A., Daamen W.F., van Kuppevelt T.H., Dijkstra P.J., et al. Tissue engineering of blood vessels: characterization of smooth-muscle cells for culturing on collagen-and-elastin-based scaffolds. Biotechnol Appl Biochem 2004, 39(Pt 2):141-149.
12. Chan-Park M.B., Shen J.Y., Cao Y., Xiong Y., Liu Y., Rayatpisheh S., et al. Biomimetic control of vascular smooth muscle cell morphology and phenotype for functional tissue-engineered small-diameter blood vessels. J Biomed Mater Res A 2009, 88A(4):1104-1121.
13. Plow E.F., Haas T.A., Zhang L., Loftus J., Smith J.W. Ligand binding to integrins. J Biol Chem 2000, 275(29):21785-21788.
14. Colognato H., Yurchenco P.D. Form and function: the laminin family of heterotrimers. Dev Dyn 2000, 218(2):213-234.
15. Leitinger B., Hohenester E. Mammalian collagen receptors. Matrix Biol 2007, 26(3):146-155.
16. Harburger D.S., Calderwood D.A. Integrin signalling at a glance. J Cell Sci 2009, 122(2):159-163.
17. Rodgers U.R., Weiss A.S. Cellular interactions with elastin. Pathol Biol 2005, 53(7):390-398.
18. Rodgers U.R., Weiss A.S. Integrin αvβ3 binds a unique non-RGD site near the C-terminus of human tropoelastin. Biochimie 2004, 86(3):173-178.
19. 3. J Biol Chem 2009, 284(42):28616-28623.
20. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110(6):673-687.
21. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
22. Pierschbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309(5963):30-33.
23. Esko J.D., Kimata K., Lindahl U. Proteoglycans and sulfated glycosaminoglycans. Essentials of glycobiology 2009, Cold Spring Harbor Laboratory Press, New York, NY. A. Varki, R.D. Cummings, J.D. Esko (Eds.).
24. Taipale J., Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997, 11(1):51-59.
25. Jeon O., Powell C., Solorio L.D., Krebs M.D., Alsberg E. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. J Control Release 2011, 154(3):258-266.
26. Xu X., Jha A.K., Duncan R.L., Jia X. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. Acta Biomater 2011, 7(8):3050-3059.
27. Lu P., Takai K., Weaver V.M., Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011, 3:12.
28. Daley W.P., Peters S.B., Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 2008, 121(3):255-264.
29. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003, 200(4):448-464.
30. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8(3):221-233.
31. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11(1):23-36.
32. Apte S.S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004, 36(6):981-985.
33. Tang B.L. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001, 33(1):33-44.
34. Stern R., Jedrzejas M.J. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006, 106(3):818-839.
35. Chan B.P., Leong K.W. Scaffolding in tissue engineering: general approaches and tissue-specific considerations. Eur Spine J 2008, 17(4):467-479.
36. Zhu J. Bioactive modification of poly(ethylene glycol) hydrogels for tissue engineering. Biomaterials 2010, 31(17):4639-4656.
37. Prestwich G.D. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res 2007, 41(1):139-148.
38. Prestwich G.D. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release 2011, 155(2):193-199.
39. Perale G., Rossi F., Sundstrom E., Bacchiega S., Masi M., Forloni G., et al. Hydrogels in spinal cord injury repair strategies. ACS Chem Neurosci 2011, 2(7):336-345.
40. Soler-Botija C., Bagó J.R., Bayes-Genis A. A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration. Ann NY Acad Sci 2012, 1254(1):57-65.
41. Johnson T.D., Christman K.L. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv 2013, 10(1):59-72.
42. Peppas N.A., Hilt J.Z., Khademhosseini A., Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater 2006, 18(11):1345-1360.
43. Hoare T.R., Kohane D.S. Hydrogels in drug delivery: progress and challenges. Polymer (Guildf) 2008, 49(8):1993-2007.
44. Zhu J., Marchant R.E. Design properties of hydrogel tissue-engineering scaffolds. Expert Rev Med Devices 2011, 8(5):607-626.
45. Seliktar D. Designing cell-compatible hydrogels for biomedical applications. Science 2012, 336(6085):1124-1128.
46. Geckil H., Xu F., Zhang X., Moon S., Demirci U. Engineering hydrogels as extracellular matrix mimics. Nanomedicine 2010, 5(3):469-484.
47. Slaughter B.V., Khurshid S.S., Fisher O.Z., Khademhosseini A., Peppas N.A. Hydrogels in regenerative medicine. Adv Mater 2009, 21(32-33):3307-3329.
48. Cushing M.C., Anseth K.S. Hydrogel cell cultures. Science 2007, 316(5828):1133-1134.
49. Brandl F., Sommer F., Goepferich A. Rational design of hydrogels for tissue engineering: impact of physical factors on cell behavior. Biomaterials 2007, 28(2):134-146.
50. Glowacki J., Mizuno S. Collagen scaffolds for tissue engineering. Biopolymers 2008, 89(5):338-344.
51. Sakai S., Hirose K., Taguchi K., Ogushi Y., Kawakami K. An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering. Biomaterials 2009, 30(20):3371-3377.
52. Daamen W.F., Veerkamp J.H., van Hest J.C.M., van Kuppevelt T.H. Elastin as a biomaterial for tissue engineering. Biomaterials 2007, 28(30):4378-4398.
53. Mol A., van Lieshout M.I., Dam-de Veen C.G., Neuenschwander S., Hoerstrup S.P., Baaijens F.P.T., et al. Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials 2005, 26(16):3113-3121.
54. MacEwan S.R., Chilkoti A. Elastin-like polypeptides: biomedical applications of tunable biopolymers. Pept Sci 2010, 94(1):60-77.
55. Lampe K.J., Antaris A.L., Heilshorn S.C. Design of three-dimensional engineered protein hydrogels for tailored control of neurite growth. Acta Biomater 2013, 9(3):5590-5599.
56. Benitez P.L., Sweet J.A., Fink H., Chennazhi K.P., Nair S.V., Enejder A., et al. Sequence-specific crosslinking of electrospun, elastin-like protein preserves bioactivity and native-like mechanics. Adv Healthcare Mater 2013, 2(1):114-118.
57. Sengupta D., Gilbert P.M., Johnson K.J., Blau H.M., Heilshorn S.C. Protein-engineered biomaterials to generate human skeletal muscle mimics. Adv Healthcare Mater 2012, 1(6):785-789.
58. McHale M.K., Setton L.A., Chilkoti A. Synthesis and in vitro evaluation of enzymatically cross-linked elastin-like polypeptide gels for cartilaginous tissue repair. Tissue Eng 2005, 11(11-12):1768-1779.
59. Lim D.W., Nettles D.L., Setton L.A., Chilkoti A. Rapid cross-linking of elastin-like polypeptides with (hydroxymethyl)phosphines in aqueous solution. Biomacromolecules 2007, 8(5):1463-1470.
60. Nowak A.P., Breedveld V., Pakstis L., Ozbas B., Pine D.J., Pochan D., et al. Rapidly recovering hydrogel scaffolds from self-assembling diblock copolypeptide amphiphiles. Nature 2002, 417(6887):424-428.
61. Pakstis L.M., Ozbas B., Hales K.D., Nowak A.P., Deming T.J., Pochan D. Effect of chemistry and morphology on the biofunctionality of self-assembling diblock copolypeptide hydrogels. Biomacromolecules 2003, 5(2):312-318.
62. Pochan D.J., Schneider J.P., Kretsinger J., Ozbas B., Rajagopal K., Haines L. Thermally reversible hydrogels via intramolecular folding and consequent self-assembly of a de novo designed peptide. J Am Chem Soc 2003, 125(39):11802-11803.
63. Ozbas B., Kretsinger J., Rajagopal K., Schneider J.P., Pochan D.J. Salt-triggered peptide folding and consequent self-assembly into hydrogels with tunable modulus. Macromolecules 2004, 37(19):7331-7337.
64. Schneider J.P., Pochan D.J., Ozbas B., Rajagopal K., Pakstis L., Kretsinger J. Responsive hydrogels from the intramolecular folding and self-assembly of a designed peptide. J Am Chem Soc 2002, 124(50):15030-15037.
65. Altunbas A., Pochan D.J. Peptide-based and polypeptide-based hydrogels for drug delivery and tissue engineering. Top Curr Chem 2012, 310:135-167.
66. DiMarco R.L., Heilshorn S.C. Multifunctional materials through modular protein engineering. Adv Mater 2012, 24(29):3923-3940.
67. Xu X., Jha A.K., Harrington D.A., Farach-Carson M.C., Jia X. Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks. Soft Matter 2012, 8(12):3280-3294.
68. Burdick J.A., Prestwich G.D. Hyaluronic acid hydrogels for biomedical applications. Adv Mater 2011, 23(12):H41-H56.
69. Toole B.P., Wight T.N., Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002, 277(7):4593-4596.
70. Toole B.P., Hascall V.C. Hyaluronan and tumor growth. Am J Pathol 2002, 161(3):745-747.
71. Liu Y., Shu X.Z., Prestwich G.D. Tumor engineering: orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan-derived hydrogels. Tissue Eng 2007, 13(5):1091-1101.
72. Xu X., Prestwich G.D. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010, 116(7):1739-1750.
73. Serban M.A., Scott A., Prestwich G.D. Use of hyaluronan-derived hydrogels for three-dimensional cell culture and tumor xenografts. Curr Protoc Cell Biol 2008, Chapter 10: Unit 10 14.
74. Jin S.G., Jeong Y.I., Jung S., Ryu H.H., Jin Y.H., Kim I.Y. The effect of hyaluronic acid on the invasiveness of malignant glioma cells: comparison of invasion potential at hyaluronic acid hydrogel and matrigel. J Korean Neurosurg Soc 2009, 46(5):472-478.
75. Ananthanarayanan B., Kim Y., Kumar S. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 2011, 32(31):7913-7923.
76. Kirker K.R., Prestwich G.D. Physical properties of glycosaminoglycan hydrogels. J Polym Sci B Polym Phys 2004, 42(23):4344-4356.
77. Cheng Y., Luo X., Payne G.F., Rubloff G.W. Biofabrication: programmable assembly of polysaccharide hydrogels in microfluidics as biocompatible scaffolds. J Mater Chem 2012, 22(16):7659-7666.
78. Ramamurthi A., Vesely I. Ultraviolet light-induced modification of crosslinked hyaluronan gels. J Biomed Mater Res A 2003, 66(2):317-329.
79. Kuo C.K., Ma P.X. Ionically crosslinked alginate hydrogels as scaffolds for tissue engineering: part 1. Structure, gelation rate and mechanical properties. Biomaterials 2001, 22(6):511-521.
80. Kim I.Y., Seo S.J., Moon H.S., Yoo M.K., Park I.Y., Kim B.C., et al. Chitosan and its derivatives for tissue engineering applications. Biotechnol Adv 2008, 26(1):1-21.
81. Sawhney A.S., Pathak C.P., Hubbell J.A. Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(.alpha-hydroxy acid) diacrylate macromers. Macromolecules 1993, 26(4):581-587.
82. Burdick J.A., Anseth K.S. Photoencapsulation of osteoblasts in injectable RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials 2002, 23(22):4315-4323.
83. Bryant S.J., Anseth K.S. Hydrogel properties influence ECM production by chondrocytes photoencapsulated in poly(ethylene glycol) hydrogels. J Biomed Mater Res 2002, 59(1):63-72.
84. Adelow C., Segura T., Hubbell J.A., Frey P. The effect of enzymatically degradable poly(ethylene glycol) hydrogels on smooth muscle cell phenotype. Biomaterials 2008, 29(3):314-326.
85. Peyton S.R., Raub C.B., Keschrumrus V.P., Putnam A.J. The use of poly(ethylene glycol) hydrogels to investigate the impact of ECM chemistry and mechanics on smooth muscle cells. Biomaterials 2006, 27(28):4881-4893.
86. Tessmar J.K., Göpferich A.M. Matrices and scaffolds for protein delivery in tissue engineering. Adv Drug Deliv Rev 2007, 59(4-5):274-291.
87. Sokolsky-Papkov M., Agashi K., Olaye A., Shakesheff K., Domb A.J. Polymer carriers for drug delivery in tissue engineering. Adv Drug Deliv Rev 2007, 59(4-5):187-206.
88. Xie J., Schultz P.G. Adding amino acids to the genetic repertoire. Curr Opin Chem Biol 2005, 9(6):548-554.
89. Wang L., Brock A., Herberich B., Schultz P.G. Expanding the genetic code of Escherichia coli. Science 2001, 292(5516):498-500.
90. Sakamoto K., Hayashi A., Sakamoto A., Kiga D., Nakayama H., Soma A., et al. Site-specific incorporation of an unnatural amino acid into proteins in mammalian cells. Nucleic Acids Res 2002, 30(21):4692-4699.
91. Cretu A., Castagnino P., Assoian R. Studying the effects of matrix stiffness on cellular function using acrylamide-based hydrogels. J Vis Exp 2010, (42).
92. Drumheller P.D., Hubbell J.A. Polymer networks with grafted cell adhesion peptides for highly biospecific cell adhesive substrates. Anal Biochem 1994, 222(2):380-388.
93. Ghosh K., Ren X.D., Shu X.Z., Prestwich G.D., Clark R.A. Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fibroblast responses critical for wound healing. Tissue Eng 2006, 12(3):601-613.
94. DeLong S.A., Moon J.J., West J.L. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 2005, 26(16):3227-3234.
95. Phelps E.A., Landázuri N., Thulé P.M., Taylor W.R., García A.J. Bioartificial matrices for therapeutic vascularization. Proc Natl Acad Sci USA 2010, 107(8):3323-3328.
96. Young J.L., Engler A.J. Hydrogels with time-dependent material properties enhance cardiomyocyte differentiation in vitro. Biomaterials 2011, 32(4):1002-1009.
97. Nuttelman C.R., Mortisen D.J., Henry S.M., Anseth K.S. Attachment of fibronectin to poly(vinyl alcohol) hydrogels promotes NIH3T3 cell adhesion, proliferation, and migration. J Biomed Mater Res 2001, 57(2):217-223.
98. Trappmann B., Gautrot J.E., Connelly J.T., Strange D.G., Li Y., Oyen M.L., et al. Extracellular-matrix tethering regulates stem-cell fate. Nat Mater 2012, 11(7):642-649.
99. Stabenfeldt S.E., Munglani G., Garcia A.J., LaPlaca M.C. Biomimetic microenvironment modulates neural stem cell survival, migration, and differentiation. Tissue Eng Part A 2010, 16(12):3747-3758.
100. Chan V., Collens M.B., Jeong J.H., Park K., Kong H., Bashir R. Directed cell growth and alignment on protein-patterned 3D hydrogels with stereolithography. Virtual Phys Prototyp 2012, 7(3):219-228.
101. Seidlits S.K., Drinnan C.T., Petersen R.R., Shear J.B., Suggs L.J., Schmidt C.E. Fibronectin-hyaluronic acid composite hydrogels for three-dimensional endothelial cell culture. Acta Biomater 2011, 7(6):2401-2409.
102. Underhill G.H., Chen A.A., Albrecht D.R., Bhatia S.N. Assessment of hepatocellular function within PEG hydrogels. Biomaterials 2007, 28(2):256-270.
103. Patel P.N., Gobin A.S., West J.L., Patrick C.W. Poly(ethylene glycol) hydrogel system supports preadipocyte viability, adhesion, and proliferation. Tissue Eng 2005, 11(9-10):1498-1505.
104. Saik J.E., Gould D.J., Watkins E.M., Dickinson M.E., West J.L. Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in biomimetic poly(ethylene glycol) hydrogels. Acta Biomater 2011, 7(1):133-143.
105. Owen S.C., Fisher S.A., Tam R.Y., Nimmo C.M., Shoichet M.S. Hyaluronic acid click hydrogels emulate the extracellular matrix. Langmuir 2013, 29(24):7393-7400.
106. Hynd M.R., Frampton J.P., Dowell-Mesfin N., Turner J.N., Shain W. Directed cell growth on protein-functionalized hydrogel surfaces. J Neurosci Methods 2007, 162(1-2):255-263.
107. Hynd M.R., Frampton J.P., Burnham M.R., Martin D.L., Dowell-Mesfin N.M., Turner J.N., et al. Functionalized hydrogel surfaces for the patterning of multiple biomolecules. J Biomed Mater Res A 2007, 81(2):347-354.
108. Cosson S., Kobel S.A., Lutolf M.P. Capturing complex protein gradients on biomimetic hydrogels for cell-based assays. Adv Funct Mater 2009, 19(21):3411-3419.
109. Zhang C., Hekmatfer S., Karuri N.W. A comparative study of polyethylene glycol hydrogels derivatized with the RGD peptide and the cell-binding domain of fibronectin. J Biomed Mater Res A 2014, 102A:170-179.
110. Shu X.Z., Ghosh K., Liu Y., Palumbo F.S., Luo Y., Clark R.A. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A 2004, 68(2):365-375.
111. Marklein R.A., Burdick J.A. Spatially controlled hydrogel mechanics to modulate stem cell interactions. Soft Matter 2010, 6(1):136-143.
112. McCall J.D., Luoma J.E., Anseth K.S. Covalently tethered transforming growth factor beta in PEG hydrogels promotes chondrogenic differentiation of encapsulated human mesenchymal stem cells. Drug Deliv Transl Res 2012, 2(5):305-312.
113. Chatani S., Nair D.P., Bowman C.N. Relative reactivity and selectivity of vinyl sulfones and acrylates towards the thiol-Michael addition reaction and polymerization. Polym Chem 2013, 4(4):1048-1055.
114. Wacker B.K., Alford S.K., Scott E.A., Das Thakur M., Longmore G.D., Elbert D.L. Endothelial cell migration on RGD-peptide-containing PEG hydrogels in the presence of sphingosine 1-phosphate. Biophys J 2008, 94(1):273-285.
115. Zisch A.H., Lutolf M.P., Ehrbar M., Raeber G.P., Rizzi S.C., Davies N., et al. Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. FASEB J 2003, 17(15):2260-2262.
116. Phelps E.A., Enemchukwu N.O., Fiore V.F., Sy J.C., Murthy N., Sulchek T.A., et al. Maleimide cross-linked bioactive PEG hydrogel exhibits improved reaction kinetics and cross-linking for cell encapsulation and in situ delivery. Adv Mater 2012, 24(1):64-70. 2.
117. Fu Y., Kao W.J. In situ forming poly(ethylene glycol)-based hydrogels via thiol-maleimide Michael-type addition. J Biomed Mater Res A 2011, 98A(2):201-211.
118. Nie T., Akins R.E., Kiick K.L. Production of heparin-containing hydrogels for modulating cell responses. Acta Biomater 2009, 5(3):865-875.
119. Lin C.C., Raza A., Shih H. PEG hydrogels formed by thiol-ene photo-click chemistry and their effect on the formation and recovery of insulin-secreting cell spheroids. Biomaterials 2011, 32(36):9685-9695.
120. Raza A., Ki C.S., Lin C.C. The influence of matrix properties on growth and morphogenesis of human pancreatic ductal epithelial cells in 3D. Biomaterials 2013, 34(21):5117-5127.
121. Polizzotti B.D., Fairbanks B.D., Anseth K.S. Three-dimensional biochemical patterning of click-based composite hydrogels via thiolene photopolymerization. Biomacromolecules 2008, 9(4):1084-1087.
122. Deforest C.A., Sims E.A., Anseth K.S. Peptide-functionalized click hydrogels with independently tunable mechanics and chemical functionality for 3D cell culture. Chem Mater 2010, 22(16):4783-4790.
123. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed 2002, 41(3):391-412.
124. Thompson L.D., Pantoliano M.W., Springer B.A. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 1994, 33(13):3831-3840.
125. Schultz G.S., Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009, 17(2):153-162.
126. Saksela O., Moscatelli D., Sommer A., Rifkin D.B. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988, 107(2):743-751.
127. Sommer A., Rifkin D.B. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989, 138(1):215-220.
128. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001, 11(5):629-634.
129. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005, 16(2):107-137.
130. Tae G., Scatena M., Stayton P.S., Hoffman A.S. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J Biomater Sci Polym Ed 2006, 17(1-2):187-197.
131. Zieris A., Chwalek K., Prokoph S., Levental K.R., Welzel P.B., Freudenberg U., et al. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J Control Release 2011, 156(1):28-36.
132. Kim M., Lee J.Y., Jones C.N., Revzin A., Tae G. Heparin-based hydrogel as a matrix for encapsulation and cultivation of primary hepatocytes. Biomaterials 2010, 31(13):3596-3603.
133. Ohta M., Suzuki Y., Chou H., Ishikawa N., Suzuki S., Tanihara M., et al. Novel heparin/alginate gel combined with basic fibroblast growth factor promotes nerve regeneration in rat sciatic nerve. J Biomed Mater Res A 2004, 71(4):661-668.
134. Locci P., Marinucci L., Lilli C., Martinese D., Becchetti E. Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res 1995, 281(2):317-324.
135. Lyon M., Deakin J.A., Rahmoune H., Fernig D.G., Nakamura T., Gallagher J.T. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J Biol Chem 1998, 273(1):271-278.
136. Catlow K., Deakin J.A., Delehedde M., Fernig D.G., Gallagher J.T., Pavao M.S., et al. Hepatocyte growth factor/scatter factor and its interaction with heparan sulphate and dermatan sulphate. Biochem Soc Trans 2003, 31(2):352-353.
137. Martino M.M., Hubbell J.A. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J 2010, 24(12):4711-4721.
138. Martino M.M., Briquez P.S., Ranga A., Lutolf M.P., Hubbell J.A. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci USA 2013, 110(12):4563-4568.
139. Macri L., Silverstein D., Clark R.A.F. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 2007, 59(13):1366-1381.
140. Mooradian D.L., Lucas R.C., Weatherbee J.A., Furcht L.T. Transforming growth factor-beta 1 binds to immobilized fibronectin. J Cell Biochem 1989, 41(4):189-200.
141. Rahman S., Patel Y., Murray J., Patel K.V., Sumathipala R., Sobel M., et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol 2005, 6(1):8.
142. 1. FEBS Lett 2006, 580(5):1376-1382.
143. Smith E.M., Mitsi M., Nugent M.A., Symes K. PDGF-A interactions with fibronectin reveal a critical role for heparan sulfate in directed cell migration during Xenopus gastrulation. Proc Natl Acad Sci USA 2009, 106(51):21683-21688.
144. Wijelath E.S., Murray J., Rahman S., Patel Y., Ishida A., Strand K., et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002, 91(1):25-31.
145. Wijelath E.S., Rahman S., Namekata M., Murray J., Nishimura T., Mostafavi-Pour Z., et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006, 99(8):853-860.
146. Bossard C., Van den Berghe L., Laurell H., Castano C., Cerutti M., Prats A.C., et al. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res 2004, 64(20):7507-7512.
147. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 2011, 3(100):100ra89.
148. Sahni A., Odrljin T., Francis C.W. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998, 273(13):7554-7559.
149. Sahni A., Francis C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000, 96(12):3772-3778.
150. De Laporte L., Rice J.J., Tortelli F., Hubbell J.A. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PLoS One 2013, 8(4):e62076.
151. Somasundaram R., Schuppan D. Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J Biol Chem 1996, 271(43):26884-26891.
152. Schuppan D., Schmid M., Somasundaram R., Ackermann R., Ruehl M., Nakamura T., et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 1998, 114(1):139-152.
153. Paralkar V.M., Vukicevic S., Reddi A.H. Transforming growth factor β type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev Biol 1991, 143(2):303-308.
154. Upton Z., Webb H., Hale K., Yandell C.A., McMurtry J.P., Francis G.L., et al. Identification of vitronectin as a novel insulin-like growth factor-II binding protein. Endocrinology 1999, 140(6):2928-2931.
155. Noble A., Towne C., Chopin L., Leavesley D., Upton Z. Insulin-like growth factor-II bound to vitronectin enhances MCF-7 breast cancer cell migration. Endocrinology 2003, 144(6):2417-2424.
156. Schoppet M., Chavakis T., Al-Fakhri N., Kanse S.M., Preissner K.T. Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. Lab Invest 2002, 82(1):37-46.
157. Tada S., Kitajima T., Ito Y. Design and synthesis of binding growth factors. Int J Mol Sci 2012, 13(5):6053-6072.
158. Tuan T.L., Cheung D.T., Wu L.T., Yee A., Gabriel S., Han B., et al. Engineering, expression and renaturation of targeted TGF-beta fusion proteins. Connect Tissue Res 1996, 34(1):1-9.
159. Andrades J.A., Han B., Becerra J., Sorgente N., Hall F.L., Nimni M.E. A recombinant human TGF-beta1 fusion protein with collagen-binding domain promotes migration, growth, and differentiation of bone marrow mesenchymal cells. Exp Cell Res 1999, 250(2):485-498.
160. Hall F.L., Kaiser A., Liu L., Chen Z.H., Hu J., Nimni M.E., et al. Design, expression, and renaturation of a lesion-targeted recombinant epidermal growth factor-von Willebrand factor fusion protein: efficacy in an animal model of experimental colitis. Int J Mol Med 2000, 6(6):635-643.
161. Andrades J.A., Santamaria J.A., Wu L.T., Hall F.L., Nimni M.E., Becerra J. Production of a recombinant human basic fibroblast growth factor with a collagen binding domain. Protoplasma 2001, 218(1-2):95-103.
162. Chen B., Lin H., Zhao Y., Wang B., Liu Y., Liu Z., et al. Activation of demineralized bone matrix by genetically engineered human bone morphogenetic protein-2 with a collagen binding domain derived from von Willebrand factor propolypeptide. J Biomed Mater Res A 2007, 80(2):428-434.
163. Visser R., Arrabal P.M., Becerra J., Rinas U., Cifuentes M. The effect of an rhBMP-2 absorbable collagen sponge-targeted system on bone formation in vivo. Biomaterials 2009, 30(11):2032-2037.
164. Han B., Perelman N., Tang B., Hall F., Shors E.C., Nimni M.E. Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model. J Orthop Res 2002, 20(4):747-755.
165. Lin H., Chen B., Sun W., Zhao W., Zhao Y., Dai J. The effect of collagen-targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds. Biomaterials 2006, 27(33):5708-5714.
166. Sun W., Lin H., Xie H., Chen B., Zhao W., Han Q., et al. Collagen membranes loaded with collagen-binding human PDGF-BB accelerate wound healing in a rabbit dermal ischemic ulcer model. Growth Factors 2007, 25(5):309-318.
167. Sun W., Lin H., Chen B., Zhao W., Zhao Y., Dai J. Promotion of peripheral nerve growth by collagen scaffolds loaded with collagen-targeting human nerve growth factor-beta. J Biomed Mater Res A 2007, 83(4):1054-1061.
168. Fan J., Xiao Z., Zhang H., Chen B., Tang G., Hou X., et al. Linear ordered collagen scaffolds loaded with collagen-binding neurotrophin-3 promote axonal regeneration and partial functional recovery after complete spinal cord transection. J Neurotrauma 2010, 27(9):1671-1683.
169. Zhang J., Ding L., Zhao Y., Sun W., Chen B., Lin H., et al. Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction. Circulation 2009, 119(13):1776-1784.
170. Lin N., Li X., Song T., Wang J., Meng K., Yang J., et al. The effect of collagen-binding vascular endothelial growth factor on the remodeling of scarred rat uterus following full-thickness injury. Biomaterials 2012, 33(6):1801-1807.
171. Yang Y., Zhao Y., Chen B., Han Q., Sun W., Xiao Z., et al. Collagen-binding human epidermal growth factor promotes cellularization of collagen scaffolds. Tissue Eng Part A 2009, 15(11):3589-3596.
172. Zhao W., Chen B., Li X., Lin H., Sun W., Zhao Y., et al. Vascularization and cellularization of collagen scaffolds incorporated with two different collagen-targeting human basic fibroblast growth factors. J Biomed Mater Res A 2007, 82(3):630-636.
173. Pang Y., Wang X., Ucuzian A.A., Brey E.M., Burgess W.H., Jones K.J., et al. Local delivery of a collagen-binding FGF-1 chimera to smooth muscle cells in collagen scaffolds for vascular tissue engineering. Biomaterials 2010, 31(5):878-885.
174. Brewster L.P., Washington C., Brey E.M., Gassman A., Subramanian A., Calceterra J., et al. Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen. Biomaterials 2008, 29(3):327-336.
175. Nishi N., Matsushita O., Yuube K., Miyanaka H., Okabe A., Wada F. Collagen-binding growth factors: production and characterization of functional fusion proteins having a collagen-binding domain. Proc Natl Acad Sci USA 1998, 95(12):7018-7023.
176. Akimoto M., Takeda A., Matsushita O., Inoue J., Sakamoto K., Hattori M., et al. Effects of CB-VEGF-A injection in rat flap models for improved survival. Plast Reconstr Surg 2013, 131(4):717-725.
177. Kitajima T., Terai H., Ito Y. A fusion protein of hepatocyte growth factor for immobilization to collagen. Biomaterials 2007, 28(11):1989-1997.
178. Lu H., Kawazoe N., Kitajima T., Myoken Y., Tomita M., Umezawa A., et al. Spatial immobilization of bone morphogenetic protein-4 in a collagen-PLGA hybrid scaffold for enhanced osteoinductivity. Biomaterials 2012, 33(26):6140-6146.
179. Ishikawa T., Terai H., Kitajima T. Production of a biologically active epidermal growth factor fusion protein with high collagen affinity. J Biochem 2001, 129(4):627-633.
180. Ishikawa T., Eguchi M., Wada M., Iwami Y., Tono K., Iwaguro H., et al. Establishment of a functionally active collagen-binding vascular endothelial growth factor fusion protein in situ. Arterioscler Thromb Vasc Biol 2006, 26(9):1998-2004.
181. Sakiyama S.E., Schense J.C., Hubbell J.A. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering. FASEB J 1999, 13(15):2214-2224.
182. Sakiyama-Elbert S.E., Hubbell J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 2000, 65(3):389-402.
183. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release 2001, 72(1-3):101-113.
184. Ichinose A., Tamaki T., Aoki N. Factor XIII-mediated cross-linking of NH2-terminal peptide of α2-plasmin inhibitor to fibrin. FEBS Lett 1983, 153(2):369-371.
185. Schense J.C., Hubbell J.A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem 1998, 10(1):75-81.
186. Sakiyama-Elbert S.E., Panitch A., Hubbell J.A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J 2001, 15(7):1300-1302.
187. Ehrbar M., Djonov V.G., Schnell C., Tschanz S.A., Martiny-Baron G., Schenk U., et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 2004, 94(8):1124-1132.
188. Schmoekel H.G., Weber F.E., Schense J.C., Gratz K.W., Schawalder P., Hubbell J.A. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng 2005, 89(3):253-262.
189. Lorentz K.M., Yang L., Frey P., Hubbell J.A. Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. Biomaterials 2012, 33(2):494-503.
190. Geer D.J., Swartz D.D., Andreadis S.T. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am J Pathol 2005, 167(6):1575-1586.
191. Hu B.-H., Messersmith P.B. Rational design of transglutaminase substrate peptides for rapid enzymatic formation of hydrogels. J Am Chem Soc 2003, 125(47):14298-14299.
192. Ehrbar M., Rizzi S.C., Schoenmakers R.G., Miguel B.S., Hubbell J.A., Weber F.E., et al. Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules 2007, 8(10):3000-3007.
193. Ehrbar M., Rizzi S.C., Hlushchuk R., Djonov V., Zisch A.H., Hubbell J.A., et al. Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials 2007, 28(26):3856-3866.
194. Agrawal V., Kishan K.V. Promiscuous binding nature of SH3 domains to their target proteins. Protein Pept Lett 2002, 9(3):185-193.
195. Vulic K., Shoichet M.S. Tunable growth factor delivery from injectable hydrogels for tissue engineering. J Am Chem Soc 2012, 134(2):882-885.
196. Beckett D., Kovaleva E., Schatz P.J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 1999, 8(4):921-929.
197. Chen I., Howarth M., Lin W., Ting A.Y. Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. Nat Methods 2005, 2(2):99-104.
198. Howarth M., Takao K., Hayashi Y., Ting A.Y. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci USA 2005, 102(21):7583-7588.
199. Wylie R.G., Ahsan S., Aizawa Y., Maxwell K.L., Morshead C.M., Shoichet M.S. Spatially controlled simultaneous patterning of multiple growth factors in three-dimensional hydrogels. Nat Mater 2011, 10(10):799-806.
200. Leipzig N.D., Wylie R.G., Kim H., Shoichet M.S. Differentiation of neural stem cells in three-dimensional growth factor-immobilized chitosan hydrogel scaffolds. Biomaterials 2011, 32(1):57-64.
201. Tam R.Y., Cooke M.J., Shoichet M.S. A covalently modified hydrogel blend of hyaluronan-methyl cellulose with peptides and growth factors influences neural stem/progenitor cell fate. J Mater Chem 2012, 22(37):19402-19411.
202. Hartley R.W. Barnase and barstar: two small proteins to fold and fit together. Trends Biochem Sci 1989, 14(11):450-454.
203. Schreiber G., Fersht A.R. Interaction of barnase with its polypeptide inhibitor barstar studied by protein engineering. Biochemistry 1993, 32(19):5145-5150.
204. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011, 18(27):4206-4214.
205. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999, 45(9):1628-1650.
206. Ogawa A., Tomita N., Kikuchi N., Sando S., Aoyama Y. Aptamer selection for the inhibition of cell adhesion with fibronectin as target. Bioorg Med Chem Lett 2004, 14(15):4001-4004.
207. Daniels D.A., Chen H., Hicke B.J., Swiderek K.M., Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 2003, 100(26):15416-15421.
208. Hicke B.J., Marion C., Chang Y.F., Gould T., Lynott C.K., Parma D. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 2001, 276(52):48644-48654.
209. Mi Z., Guo H., Russell M.B., Liu Y., Sullenger B.A., Kuo P.C. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009, 17(1):153-161.
210. Green L.S., Jellinek D., Jenison R., Östman A., Heldin C.-H., Janjic N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 1996, 35(45):14413-14424.
211. Potty A.S.R., Kourentzi K., Fang H., Jackson G.W., Zhang X., Legge G.B., et al. Biophysical characterization of DNA aptamer interactions with vascular endothelial growth factor. Biopolymers 2009, 91(2):145-156.
212. Jellinek D., Lynott C.K., Rifkin D.B., Janjić N. High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc Natl Acad Sci USA 1993, 90(23):11227-11231.
213. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5(2):123-132.
214. Pagratis N.C., Bell C., Chang Y.F., Jennings S., Fitzwater T., Jellinek D., et al. Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol 1997, 15(1):68-73.
215. Jellinek D., Green L.S., Bell C., Lynott C.K., Gill N., Vargeese C., et al. Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 1995, 34(36):11363-11372.
216. Green L.S., Jellinek D., Bell C., Beebe L.A., Feistner B.D., Gill S.C., et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995, 2(10):683-695.
217. Xiao J., Carter J.A., Frederick K.A., McGown L.B. A genome-inspired DNA ligand for the affinity capture of insulin and insulin-like growth factor-2. J Sep Sci 2009, 32(10):1654-1664.
218. Kang J., Lee M.S., Copland J.A., Luxon B.A., Gorenstein D.G. Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein. Bioorg Med Chem Lett 2008, 18(6):1835-1839.
219. McCauley T.G., Kurz J.C., Merlino P.G., Lewis S.D., Gilbert M., Epstein D.M., et al. Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm Res 2006, 23(2):303-311.
220. White R.R., Roy J.A., Viles K.D., Sullenger B.A., Kontos C.D. A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function. Angiogenesis 2008, 11(4):395-401.
221. White R.R., Shan S., Rusconi C.P., Shetty G., Dewhirst M.W., Kontos C.D. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003, 100(9):5028-5033.
222. Zhang Z., Guo L., Tang J., Guo X., Xie J. An aptameric molecular beacon-based "signal-on" approach for rapid determination of rHuEPOα. Talanta 2009, 80(2):985-990.
223. Orava E.W., Jarvik N., Shek Y.L., Sidhu S.S., Gariepy J. A short DNA aptamer that recognizes TNFalpha and blocks its activity in vitro. ACS Chem Biol 2013, 8(1):170-178.
224. Kubik M.F., Bell C., Fitzwater T., Watson S.R., Tasset D.M. Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. J Immunol 1997, 159(1):259-267.
225. Ishiguro A., Akiyama T., Adachi H., Inoue J., Nakamura Y. Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum 2011, 63(2):455-466.
226. Soontornworajit B., Zhou J., Shaw M.T., Fan T.-H., Wang Y. Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. Chem Commun 2010, 46(11):1857-1859.
227. Soontornworajit B., Zhou J., Zhang Z., Wang Y. Aptamer-functionalized in situ injectable hydrogel for controlled protein release. Biomacromolecules 2010, 11(10):2724-2730.
228. Battig M.R., Soontornworajit B., Wang Y. Programmable release of multiple protein drugs from aptamer-functionalized hydrogels via nucleic acid hybridization. J Am Chem Soc 2012, 134(30):12410-12413.
229. Shangguan D., Li Y., Tang Z., Cao Z.C., Chen H.W., Mallikaratchy P., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006, 103(32):11838-11843.
230. Chen N., Zhang Z., Soontornworajit B., Zhou J., Wang Y. Cell adhesion on an artificial extracellular matrix using aptamer-functionalized PEG hydrogels. Biomaterials 2012, 33(5):1353-1362.
231. Li S., Chen N., Zhang Z., Wang Y. Endonuclease-responsive aptamer-functionalized hydrogel coating for sequential catch and release of cancer cells. Biomaterials 2013, 34(2):460-469.
232. Zhang Z., Chen N., Li S., Battig M.R., Wang Y. Programmable hydrogels for controlled cell catch and release using hybridized aptamers and complementary sequences. J Am Chem Soc 2012, 134(38):15716-15719.
233. Burdick J.A., Murphy W.L. Moving from static to dynamic complexity in hydrogel design. Nat Commun 2012, 3:1269.
234. Wilkinson A.E., McCormick A.M., Leipzig N.D. Central nervous system tissue engineering: current considerations and strategies. Synthesis Lect Tissue Eng 2011, 3(2):1-120.
235. Katti D.S., Lakshmi S., Langer R., Laurencin C.T. Toxicity, biodegradation and elimination of polyanhydrides. Adv Drug Deliv Rev 2002, 54(7):933-961.
236. Tayebjee M.H., Lip G.Y., Blann A.D., Macfadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 2005, 115(3):205-210.
237. Sahoo S., Chung C., Khetan S., Burdick J.A. Hydrolytically degradable hyaluronic acid hydrogels with controlled temporal structures. Biomacromolecules 2008, 9(4):1088-1092.
238. Patterson J., Siew R., Herring S.W., Lin A.S., Guldberg R., Stayton P.S. Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration. Biomaterials 2010, 31(26):6772-6781.
239. West J.L., Hubbell J.A. Photopolymerized hydrogel materials for drug delivery applications. React Polym 1995, 25(2-3):139-147.
240. Zhao X., Harris J.Milton Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein. J Pharm Sci 1998, 87(11):1450-1458.
241. Elbert D.L., Pratt A.B., Lutolf M.P., Halstenberg S., Hubbell J.A. Protein delivery from materials formed by self-selective conjugate addition reactions. J Control Release 2001, 76(1-2):11-25.
242. Zustiak S.P., Leach J.B. Hydrolytically degradable poly(ethylene glycol) hydrogel scaffolds with tunable degradation and mechanical properties. Biomacromolecules 2010, 11(5):1348-1357.
243. Cho E., Kutty J.K., Datar K., Soo Lee J., Vyavahare N.R., Webb K. A novel synthetic route for the preparation of hydrolytically degradable synthetic hydrogels. J Biomed Mater Res A 2009, 90A(4):1073-1082.
244. Jo Y.S., Gantz J., Hubbell J.A., Lutolf M.P. Tailoring hydrogel degradation and drug release via neighboring amino acid controlled ester hydrolysis. Soft Matter 2009, 5(2):440-446.
245. Drury J.L., Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24(24):4337-4351.
246. Sargeant T.D., Desai A.P., Banerjee S., Agawu A., Stopek J.B. An in situ forming collagen-PEG hydrogel for tissue regeneration. Acta Biomater 2012, 8(1):124-132.
247. Ahmed T.A., Griffith M., Hincke M. Characterization and inhibition of fibrin hydrogel-degrading enzymes during development of tissue engineering scaffolds. Tissue Eng 2007, 13(7):1469-1477.
248. Afify A.M., Stern M., Guntenhoner M., Stern R. Purification and characterization of human serum hyaluronidase. Arch Biochem Biophys 1993, 305(2):434-441.
249. Oh E.J., Kang S.W., Kim B.S., Jiang G., Cho I.H., Hahn S.K. Control of the molecular degradation of hyaluronic acid hydrogels for tissue augmentation. J Biomed Mater Res A 2008, 86(3):685-693.
250. Nilasaroya A., Martens P.J., Whitelock J.M. Enzymatic degradation of heparin-modified hydrogels and its effect on bioactivity. Biomaterials 2012, 33(22):5534-5540.
251. West J.L., Hubbell J.A. Polymeric biomaterials with degradation sites for proteases involved in cell migration. Macromolecules 1998, 32(1):241-244.
252. Mann B.K., Gobin A.S., Tsai A.T., Schmedlen R.H., West J.L. Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering. Biomaterials 2001, 22(22):3045-3051.
253. Brandl F.P., Seitz A.K., Tessmar J.K., Blunk T., Gopferich A.M. Enzymatically degradable poly(ethylene glycol) based hydrogels for adipose tissue engineering. Biomaterials 2010, 31(14):3957-3966.
254. Kraehenbuehl T.P., Zammaretti P., Van der Vlies A.J., Schoenmakers R.G., Lutolf M.P., Jaconi M.E., et al. Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials 2008, 29(18):2757-2766.
255. Ehrbar M., Sala A., Lienemann P., Ranga A., Mosiewicz K., Bittermann A., et al. Elucidating the role of matrix stiffness in 3D cell migration and remodeling. Biophys J 2011, 100(2):284-293.
256. Khetan S., Guvendiren M., Legant W.R., Cohen D.M., Chen C.S., Burdick J.A. Degradation-mediated cellular traction directs stem cell fate in covalently crosslinked three-dimensional hydrogels. Nat Mater 2013, 12(5):458-465.
257. Lévesque S.G., Shoichet M.S. Synthesis of enzyme-degradable, peptide-cross-linked dextran hydrogels. Bioconjug Chem 2007, 18(3):874-885.
258. Stephan M.T., Moon J.J., Um S.H., Bershteyn A., Irvine D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010, 16(9):1035-1041.
259. Stephan M.T., Stephan S.B., Bak P., Chen J., Irvine D.J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 2012, 33(23):5776-5787.
260. Holden C.A., Yuan Q., Yeudall W.A., Lebman D.A., Yang H. Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery. Int J Nanomedicine 2010, 5:25-36.
261. Christian D.A., Hunter C.A. Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy 2012, 4(4):425-441.
262. Morachis J.M., Mahmoud E.A., Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev 2012, 64(3):505-519.
263. Serda R.E. Particle platforms for cancer immunotherapy. Int J Nanomed 2013, 8:1683-1696.
264. Leong Y.S., Candau F. Inverse microemulsion polymerization. J Phys Chem 1982, 86(13):2269-2271.
265. Mitra S., Gaur U., Ghosh P.C., Maitra A.N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001, 74(1-3):317-323.
266. Lee H., Mok H., Lee S., Oh Y.K., Park T.G. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release 2007, 119(2):245-252.
267. Braun O., Selb J., Candau F. Synthesis in microemulsion and characterization of stimuli-responsive polyelectrolytes and polyampholytes based on N-isopropylacrylamide. Polymer (Guildf) 2001, 42(21):8499-8510.
268. Fernandez V.V.A., Tepale N., Sánchez-Díaz J.C., Mendizábal E., Puig J.E., Soltero J.F.A. Thermoresponsive nanostructured poly(N-isopropylacrylamide) hydrogels made via inverse microemulsion polymerization. Colloid Polym Sci 2006, 284(4):387-395.
269. Juraničová V., Kawamoto S., Fujimoto K., Kawaguchi H., Bartoň J. Inverse microemulsion polymerization of acrylamide in the presence of N,N-dimethylacrylamide. Die Angew Makromol Chem 1998, 258(1):27-31.
270. Bartoň J. Inverse microemulsion polymerization of oil-soluble monomers in the presence of hydrophilic polyacrylamide nanoparticles. Macromol Symp 2002, 179(1):189-208.
271. Kaneda I., Sogabe A., Nakajima H. Water-swellable polyelectrolyte microgels polymerized in an inverse microemulsion using a nonionic surfactant. J Colloid Interface Sci 2004, 275(2):450-457.
272. Gaur U., Sahoo S.K., De T.K., Ghosh P.C., Maitra A., Ghosh P.K. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000, 202(1-2):1-10.
273. Bharali D.J., Sahoo S.K., Mozumdar S., Maitra A. Cross-linked polyvinylpyrrolidone nanoparticles: a potential carrier for hydrophilic drugs. J Colloid Interface Sci 2003, 258(2):415-423.
274. Missirlis D., Tirelli N., Hubbell J.A. Amphiphilic hydrogel nanoparticles. preparation, characterization, and preliminary assessment as new colloidal drug carriers. Langmuir 2005, 21(6):2605-2613.
275. Oh J.K., Perineau F., Matyjaszewski K. Preparation of nanoparticles of well-controlled water-soluble homopolymers and block copolymers using an inverse miniemulsion ATRP. Macromolecules 2006, 39(23):8003-8010.
276. Oh J.K., Tang C., Gao H., Tsarevsky N.V., Matyjaszewski K. Inverse miniemulsion ATRP: a new method for synthesis and functionalization of well-defined water-soluble/cross-linked polymeric particles. J Am Chem Soc 2006, 128(16):5578-5584.
277. Genggeng Q., Christopher W.J., Schork F.J. RAFT inverse miniemulsion polymerization of acrylamide. Macromol Rapid Commun 2007, 28(9):1010-1016.
278. Oh J.K., Dong H., Zhang R., Matyjaszewski K., Schlaad H. Preparation of nanoparticles of double-hydrophilic PEO-PHEMA block copolymers by AGET ATRP in inverse miniemulsion. J Polym Sci A Polym Chem 2007, 45(21):4764-4772.
279. An Z., Shi Q., Tang W., Tsung C.K., Hawker C.J., Stucky G.D. Facile RAFT precipitation polymerization for the microwave-assisted synthesis of well-defined, double hydrophilic block copolymers and nanostructured hydrogels. J Am Chem Soc 2007, 129(46):14493-14499.
280. An Z., Tang W., Wu M., Jiao Z., Stucky G.D. Heterofunctional polymers and core-shell nanoparticles via cascade aminolysis/Michael addition and alkyne-azide click reaction of RAFT polymers. Chem Commun (Camb) 2008, (48):6501-6503.
281. Shen W., Chang Y., Liu G., Wang H., Cao A., An Z. Biocompatible, antifouling, and thermosensitive core-shell nanogels synthesized by RAFT aqueous dispersion polymerization. Macromolecules 2011, 44(8):2524-2530.
282. Rieger J., Grazon C., Charleux B., Alaimo D., Jér≄me C. Pegylated thermally responsive block copolymer micelles and nanogels via in situ RAFT aqueous dispersion polymerization. J Polym Sci A Polym Chem 2009, 47(9):2373-2390.
283. Rider C.C. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans 2006, 34(Pt 3):458-460.
284. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4(12):1317-1326.
285. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010, 21(5):687-690.
286. Raines E.W., Ross R. Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences. J Cell Biol 1992, 116(2):533-543.
287. Rolny C., Spillmann D., Lindahl U., Claesson-Welsh L. Heparin amplifies platelet-derived growth factor (PDGF)- BB-induced PDGF alpha -receptor but not PDGF beta-receptor tyrosine phosphorylation in heparan sulfate-deficient cells. Effects on signal transduction and biological responses. J Biol Chem 2002, 277(22):19315-19321.
288. Lyon M., Deakin J.A., Mizuno K., Nakamura T., Gallagher J.T. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994, 269(15):11216-11223.
289. Ohkawara B., Iemura S., ten Dijke P., Ueno N. Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol 2002, 12(3):205-209.
290. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237(1):295-302.
291. Irie A., Habuchi H., Kimata K., Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 2003, 308(4):858-865.